Fox CP, et al. - Researchers sought to enhance their understanding concerning the clinical characteristics and outcomes of patients with extranodal natural killer (NK) T-cell lymphoma (ENKTL), a unique clinicopathological entity, typically linked with poor survival outcomes. They conducted a substudy of the T-cell Project, a global prospective cohort study that included adults (> 18 years) with newly diagnosed, untreated mature T-cell or NK lymphomas (WHO 2001 or 2008 classifications) from 74 centers in 13 countries (in Asia, Europe, North America, and South America). In the T-cell Project, enrollment of 1,695 patients with mature T-cell or NK lymphomas was done from Oct 12, 2006, to Feb 28, 2018. ENKTL was diagnosed in 166 patients, comprising 11% of 1,553 eligible registered cases and distributed across 40 participating centers in four continents. At a median follow-up of 44 months (IQR 20–61), overall survival rate of 54% (95% CI 44–63) was observed at 5 years among patients with nasal disease (n = 98) and 34% (27–46) in patients with extranasal disease (n = 68). This study reports the outcomes from the largest international cohort of patients with ENKTL till date. Over the past decade, a clinically significant improvement was observed in the survival of patients with ENKTL treated in routine clinical practice; this improvement is likely to be due to the increasing use of treatment protocols specific for ENKTL.